Harvard Bioscience, Inc. Revenue 2009–2025
Harvard Bioscience, Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Harvard Bioscience, Inc. revenue for the quarter ending March 31, 2026 was 20.8 M, a 4.68% decrease year-over-year.
- Harvard Bioscience, Inc. revenue for the twelve months ending March 31, 2026 was 83.6 M, a 11.98% decrease year-over-year.
- Harvard Bioscience, Inc. annual revenue for 2025 was 86.5 M, a 8.06% decrease from 2024.
- Harvard Bioscience, Inc. annual revenue for 2024 was 94.1 M, a 16.14% decrease from 2023.
- Harvard Bioscience, Inc. annual revenue for 2023 was 112.3 M, a 0.96% decrease from 2022.
- Harvard Bioscience, Inc. annual revenue for 2022 was 113.3 M.
Harvard Bioscience, Inc. (HBIO) — Frequently Asked Questions
Harvard Bioscience, Inc. (HBIO) is a publicly traded US company. It has a market capitalization of $275M. In fiscal 2025 it reported revenue of $87M and net income of -$57M. Explore HBIO's stock price, financial statements, earnings history, margins and key ratios below.
What is Harvard Bioscience, Inc.'s market cap?
Harvard Bioscience, Inc. (HBIO) has a market capitalization of $275M.
What is the HBIO stock price?
HBIO trades at $6.20 (+2.65% on the day).
How much revenue does Harvard Bioscience, Inc. make?
Harvard Bioscience, Inc. reported revenue of $87M in fiscal 2025.
Is HBIO profitable?
In fiscal 2025, Harvard Bioscience, Inc. reported net income of -$57M.